Related references
Note: Only part of the references are listed.Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small-cell lung cancer: an open-label phase II multicentre trial (COVeRT study)
Nimit Singhal et al.
ANTI-CANCER DRUGS (2015)
Identification of novel drugs to target dormant micrometastases
Robert E. Hurst et al.
BMC CANCER (2015)
New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice
Shuichi Sakamoto et al.
CANCER SCIENCE (2015)
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial
Linda Dirven et al.
EUROPEAN JOURNAL OF CANCER (2015)
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia
H. Hirte et al.
GYNECOLOGIC ONCOLOGY (2015)
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial
Kathleen N. Moore et al.
GYNECOLOGIC ONCOLOGY (2015)
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: A An NRG Oncology/Gynecologic Oncology Group Study 0229N
Vicky Makker et al.
GYNECOLOGIC ONCOLOGY (2015)
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
David Bender et al.
GYNECOLOGIC ONCOLOGY (2015)
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal H. Machiels et al.
LANCET ONCOLOGY (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer
Jason B. Ross et al.
NATURE CELL BIOLOGY (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The emerging molecular machinery and therapeutic targets of metastasis
Yutong Sun et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer A Model for Rational Accelerated Drug Development
Arjun V. Balar et al.
UROLOGIC CLINICS OF NORTH AMERICA (2015)
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy
Hilary A. Kenny et al.
NATURE COMMUNICATIONS (2015)
A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia
Jin Wang et al.
ONCOTARGET (2015)
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Abhisek Mitra et al.
ONCOTARGET (2015)
Investigating Breast Cancer Cell Behavior Using Tissue Engineering Scaffolds
Khadidiatou Guiro et al.
PLOS ONE (2015)
Metastasis prevention by targeting the dormant niche
Cyrus M. Ghajar
NATURE REVIEWS CANCER (2015)
Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system
S. E. Wheeler et al.
BRITISH JOURNAL OF CANCER (2014)
The Inherent Premise of Immunotherapy for Cancer Dormancy
Masoud H. Manjili
CANCER RESEARCH (2014)
Cancer Cell Dormancy in Novel Mouse Models for Reversible Pancreatic Cancer: A Lingering Challenge in the Development of Targeted Therapies
Wan-Chi Lin et al.
CANCER RESEARCH (2014)
Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics
Jing Xia et al.
CLINICAL CANCER RESEARCH (2014)
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells
Lara H. El Touny et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Cocultures of Mesenchymal Stem Cells and Endothelial Cells As Organotypic Models of Prostate Cancer Metastasis
Mark S. K. Chong et al.
MOLECULAR PHARMACEUTICS (2014)
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Andrea Viale et al.
NATURE (2014)
Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression
Lora C. Bailey-Downs et al.
PLOS ONE (2014)
Mechanisms of disseminated cancer cell dormancy: an awakening field
Maria Soledad Sosa et al.
NATURE REVIEWS CANCER (2014)
Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients
Yang Yang et al.
CANCER (2013)
Why does cancer therapy lack effective anti-metastasis drugs?
Georg F. Weber
CANCER LETTERS (2013)
A Novel Model of Dormancy for Bone Metastatic Breast Cancer Cells
Rebecca Marlow et al.
CANCER RESEARCH (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
The perivascular niche regulates breast tumour dormancy
Cyrus M. Ghajar et al.
NATURE CELL BIOLOGY (2013)
Suppression and Activation of the Malignant Phenotype by Extracellular Matrix in Xenograft Models of Bladder Cancer: A Model for Tumor Cell Dormancy
Robert E. Hurst et al.
PLOS ONE (2013)
Mechanisms of Metastatic Tumor Dormancy
Mary Osisami et al.
JOURNAL OF CLINICAL MEDICINE (2013)
A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies
Carolyn G. Marsden et al.
BMC CANCER (2012)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Solange Landreville et al.
CLINICAL CANCER RESEARCH (2012)
The metastatic microenvironment: Brain-residing melanoma metastasis and dormant micrometastasis
Sivan Izraely et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Effect of Inhibition of the Lysophosphatidic Acid Receptor 1 on Metastasis and Metastatic Dormancy in Breast Cancer
Jean-Claude A. Marshall et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Dormancy Signatures and Metastasis in Estrogen Receptor Positive and Negative Breast Cancer
Ryung S. Kim et al.
PLOS ONE (2012)
VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging α4β1-Positive Osteoclast Progenitors
Xin Lu et al.
CANCER CELL (2011)
Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone
Aya Kobayashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
AACR Centennial Series: The Biology of Cancer Metastasis: Historical Perspective
James E. Talmadge et al.
CANCER RESEARCH (2010)
Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth
Dalit Barkan et al.
EUROPEAN JOURNAL OF CANCER (2010)
Modeling metastasis biology and therapy in real time in the mouse lung
Arnulfo Mendoza et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
Dragana Milojkovic et al.
CLINICAL CANCER RESEARCH (2009)
Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton
Dalit Barkan et al.
CANCER RESEARCH (2008)
Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis
Dingcheng Gao et al.
SCIENCE (2008)
Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-Medicare data
Michael E. Stokes et al.
VALUE IN HEALTH (2008)
Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy
Kevin T. Nash et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Heparanase, hyaluronan, and CD44 in cancers:: A breast carcinoma perspective
Martin Gotte et al.
CANCER RESEARCH (2006)
Tumor cell dormancy induced by p38SAPK and ER-stress signaling -: An adaptive advantage for metastatic cells?
Aparna C. Ranganathan et al.
CANCER BIOLOGY & THERAPY (2006)
A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel
RE Hurst et al.
CANCER LETTERS (2005)
Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors
JW Gray
CANCER CELL (2003)